Unimpeded by Allergan’s Botox Dominance, Amgen/Novartis’ Aimovig, Teva’s Ajovy, and Eli Lilly’s Emgality Use at the Patient Level is More Robust Within the Episodic Migraine Segment Than Physicians Are Aware of
Teva’s Ajovy may be most at risk by the future availability of orally dosed anti-CGRP therapies, including Biohaven’s rimegepant and Allergan’s atogepant, while Allergan’s Botox will remain insulated from anti-CGRP class pressure, according to the inaugural Spherix Global Insights audit of the US migraine prevention market EXTON, Pa., September 11, 2019 ― Contributing physicians appear […]
With Continued Uptake in the US, Both EMD Serono’s Mavenclad and Novartis’ Mayzent Must Successfully Woo Multiple Sclerosis Patient Candidates from Genentech’s Ocrevus (and Each Other) to Succeed, According to the 15th Wave of the Quarterly Spherix Global Insights Report
Genentech’s best strategy for escaping the competitive pressure from these new oral market entrants, as well as future monoclonal antibodies like Novartis’ ofatumumab and TG Therapeutics’ ublituximab, will be the continued execution on establishing Ocrevus as a preferred first-line option in the relapsing-remitting multiple sclerosis treatment algorithm EXTON, Pa., September 9, 2019 ― Four months […]
Recent Studies Reveal Flare Rates Among Dupixent-Treated Patients with Moderate-to-Severe Atopic Dermatitis
Spherix Global Insights provides an independent perspective on the atopic dermatitis market. EXTON, Pa., September 5, 2019 /PRNewswire/ — Atopic dermatitis (AD), commonly referred to as eczema, affects millions of children and adults across the globe. In 2017, Regeneron/Sanofi’s Dupixent, an IL-4/13 blocker, became the first approved biologic to treat adults with more severe forms of […]
Biosimilars and JAK Inhibitors Continue to Gain Popularity in the EU Rheumatoid Arthritis Market, According to Spherix Global Insights
Biosimilar use in the EU5 rheumatoid arthritis market leads to erosion of name brand drugs; JAK inhibitors slowly penetrate the market, while perceived safety risks may limit prescribing EXTON, Pa., Aug. 30, 2019 /PRNewswire/ — Twice a year, Spherix collects the responses of ~250 EU5 rheumatologists as part of their RealTime Dynamix™: Rheumatoid Arthritis (EU) […]
Spherix Global Insights Named One of Philadelphia’s Fastest Growing Companies
Independent market intelligence firm earns a spot on Philadelphia Business Journal’s Soaring 76 list of fastest growing companies in the Greater Philadelphia area EXTON, Pa., August 26, 2019 ― Spherix Global Insights, a market intelligence firm providing biopharma clients an independent perspective within immunology, nephrology, and neurology markets, made the list of distinguished companies identified […]
Novartis’ Gilenya, Sanofi’s Aubagio, Biogen’s Tysabri and Tecfidera Capture the Majority of Recent Switches in the European Multiple Sclerosis Market Boosted by Frequent Neurologist Endorsement
Although overall switch share for Roche’s Ocrevus is hampered by low treatment and switch rates for primary progressive multiple sclerosis, European neurologists vastly underestimate the dominance of the brand among such treated patients as revealed in the new audit by Spherix Global Insights EXTON, Pa., August 13, 2019 ― According to Spherix’s new audit included […]
US Nephrologists Are Optimistic About the Potential for Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHIs) for the Treatment of Renal Anemia
According to Spherix Global Insights, nephrologists have high expectations that this novel class of oral agents may offer a safer way to treat renal anemia compared to erythropoietin stimulating agents (ESAs) such as Amgen’s Epogen and Aranesp EXTON, Pa., August 1, 2019 / PRNewswire/ – In the latest report included in the RealTime Dynamix: Renal […]
Robust Use of Janssen’s Tremfya and Positive Early Launch Metrics for AbbVie’s Skyrizi May Threaten Growth of IL-17 Inhibitors in US Psoriasis Market, According to Spherix Global Insights
The US psoriasis landscape has come a long way since the first introduction of an alternate mechanism of action agent in a previously TNF-dominant market; IL-23 inhibitors are now in the spotlight EXTON, Pa., July 25, 2019 /PRNewswire/ — Spherix began tracking the US psoriasis market through its RealTime Dynamix™: Psoriasis (US) service in early […]
Launch of AbbVie’s Upadacitinib Expected to Cause a Stir in the US Rheumatoid Arthritis Market, According to Spherix Global Insights
As the user base of Regeneron’s Kevzara and Eli Lilly’s Olumiant continue to expand, US rheumatologists gear up for AbbVie’s JAK inhibitor to enter the market – with Pfizer’s Xeljanz most at risk for displacement Download Report Overview EXTON, Pa., July 18, 2019 /PRNewswire/ — The latest report included in Spherix’s RealTime Dynamix™ Rheumatoid Arthritis (US) […]
Uptake of Biosimilars in the EU5 Blunts Share of AbbVie’s Humira and Merck’s Remicade in the Crohn’s Disease and Ulcerative Colitis Markets, While a Black Cloud of Safety Concerns Still Follows Pfizer’s Xeljanz
A new report by Spherix Global Insights includes the responses of 255 EU5 gastroenterologists and reveals which brands are being affected by the current climate of the IBD market Download Report Overview EXTON, Pa., July 16, 2019 /PRNewswire/ — According to the latest report published as part of Spherix’s RealTime Dynamix™: Inflammatory Bowel Disease (EU) service, […]
